BioLine RX Ltd
TASE:BLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioLine RX Ltd
Cash from Financing Activities
BioLine RX Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Cash from Financing Activities
$8.9m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-11%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Financing Activities
-$18.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-11%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash from Financing Activities
$10.4m
|
CAGR 3-Years
311%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Financing Activities
$39.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Financing Activities
$13.7m
|
CAGR 3-Years
1 011%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash from Financing Activities
$12.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-3%
|
|
BioLine RX Ltd
Glance View
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
See Also
What is BioLine RX Ltd's Cash from Financing Activities?
Cash from Financing Activities
8.9m
USD
Based on the financial report for Dec 31, 2025, BioLine RX Ltd's Cash from Financing Activities amounts to 8.9m USD.
What is BioLine RX Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-11%
Over the last year, the Cash from Financing Activities growth was -57%. The average annual Cash from Financing Activities growth rates for BioLine RX Ltd have been -24% over the past three years , -13% over the past five years , and -11% over the past ten years .
